CCL5 and familial pancreatic carcinoma: Its interaction with the ligand CCL5 promotes the migration and invasiveness of pancreatic cancer cells, and preclinical studies have shown that pharmacological blockade of CCR5 can significantly reduce tumor growth in murine models of pancreatic cancer [2,75].